Tags: cell | therapy | heart | failure

FDA to Fast Track Cell Therapy for Heart Failure

FDA to Fast Track Cell Therapy for Heart Failure
(Copyright DPC)

Thursday, 21 December 2017 03:06 PM

Australian drug developer Mesoblast Ltd. said on Thursday the U.S. Food and Drug Administration would fast track the review of its cell therapy treatment for heart failure patients under a new designation rolled out last December.

Mesoblast's mesenchymal precursor cell (MPC) therapy, aiming to mitigate advanced heart failure, received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, the company said.

The designation is based on the preliminary clinical trial data, the company said, adding that a mid-stage trial was being conducted in 159 patients with heart failure and left ventricular assist devices (LVADs).

A single dose consists of 150 million highly purified stem cells that are delivered directly to the heart's left ventricle by injection or catheter, reducing inflammation and increasing blood flow to spur blood vessel formation that helps repair the heart muscle.

Mesoblast is seen as among the farthest along in the stem cell industry at a time when Wall Street investors have focused on potentially big payoffs from immune-system based cancer therapies and rare diseases.

© 2020 Thomson/Reuters. All rights reserved.


   
1Like our page
2Share
Health-News
the FDA plans to fast track its review of an Australian drug developer's cell therapy treatment for heart failure patients.
cell, therapy, heart, failure
168
2017-06-21
Thursday, 21 December 2017 03:06 PM
Newsmax Media, Inc.
 
Newsmax TV Live

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved